

3401 Princeton Pike, Lawrenceville, NJ 08648

Notice Regarding Adjustment of 340B Prices for Select Product of Bristol Myers Squibb

March 10, 2022

Bristol Myers Squibb (BMS) has recalculated its provisional 340B ceiling price for the product below for Q3 2021. Recalculated pricing now incorporates actual Medicaid pricing calculations for the quarter, which were not available at the time of the new NDC's launch. BMS has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about BMS' recalculation affecting certain 340B Covered Entities for the impacted product.

BMS has determined the amount owed to each affected covered entity. Credits will be provided to these entities through the wholesaler accounts where the product was purchased.

Product	Description	NDC Number
OPDIVO®	120 mg (1VLx12mL)	00003-3756-14

If a Covered Entity believes they are due a refund and is not provided this refund through its wholesaler by March 31, 2022, please contact Margarita.Womelsdorf@bms.com.